Concert Pharma Shares Down 26.56% Despite Earlier FDA Grant Of Fast Track Designation For CTP-543; Mizuho Downgraded Shares To Neutral Citing Patent Board Decision Not To Grant Company A Post Grant Review In Litigation With Incyte Over CTP-543